NervGen Pharma Corp. announced that the Board of Directors and Paul Brennan have mutually agreed that Mr. Brennan will step down as President & Chief Executive Officer and a member of the Board, effective immediately. The Board of Directors has appointed current Board member Dr. Adam Rogers as interim President.

Mr. Brennan will serve as a strategic advisor to management and the Board during the transition period. Adam Rogers, MD, is a Principal of Boston-based PFP Biosciences Holdings and a board-certified ophthalmologist specializing in diseases and surgery of the retina and vitreous. Dr. Rogers co-founded Hemera Biosciences in 2010, a clinical stage gene therapy company targeting dry age-related macular degeneration.

He assumed the role of CEO in 2017 and oversaw all aspects of Hemera until it was acquired in December 2020 by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.